169 related articles for article (PubMed ID: 37345470)
1. Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia.
Pagano G; Botana IF; Wierz M; Roessner PM; Ioannou N; Zhou X; Al-Hity G; Borne C; Gargiulo E; Gonder S; Qu B; Stamatopoulos B; Ramsay AG; Seiffert M; Largeot A; Moussay E; Paggetti J
Haematologica; 2023 Nov; 108(11):3011-3024. PubMed ID: 37345470
[TBL] [Abstract][Full Text] [Related]
2. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
Alhakeem SS; McKenna MK; Oben KZ; Noothi SK; Rivas JR; Hildebrandt GC; Fleischman RA; Rangnekar VM; Muthusamy N; Bondada S
J Immunol; 2018 Jun; 200(12):4180-4189. PubMed ID: 29712773
[TBL] [Abstract][Full Text] [Related]
3. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
Manna A; Kellett T; Aulakh S; Lewis-Tuffin LJ; Dutta N; Knutson K; Chini E; Pinilla-Ibarz J; Lamanna N; Manochakian R; Malavasi F; Sher T; Chanan-Khan AA; Ailawadhi S; Paulus A
Blood Adv; 2020 May; 4(10):2143-2157. PubMed ID: 32421811
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
8. T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.
Oldreive CE; Skowronska A; Davies NJ; Parry H; Agathanggelou A; Krysov S; Packham G; Rudzki Z; Cronin L; Vrzalikova K; Murray P; Odintsova E; Pratt G; Taylor AM; Moss P; Stankovic T
Dis Model Mech; 2015 Nov; 8(11):1401-12. PubMed ID: 26398941
[TBL] [Abstract][Full Text] [Related]
9. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
Hanna BS; Öztürk S; Seiffert M
Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
[TBL] [Abstract][Full Text] [Related]
10. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses.
Gargiulo E; Viry E; Morande PE; Largeot A; Gonder S; Xian F; Ioannou N; Benzarti M; Kleine Borgmann FB; Mittelbronn M; Dittmar G; Nazarov PV; Meiser J; Stamatopoulos B; Ramsay AG; Moussay E; Paggetti J
Blood Cancer Discov; 2023 Jan; 4(1):54-77. PubMed ID: 36108149
[TBL] [Abstract][Full Text] [Related]
14. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
[TBL] [Abstract][Full Text] [Related]
15. Control of chronic lymphocytic leukemia development by clonally-expanded CD8
Hanna BS; Roessner PM; Yazdanparast H; Colomer D; Campo E; Kugler S; Yosifov D; Stilgenbauer S; Schmidt M; Gabriel R; Lichter P; Seiffert M
Leukemia; 2019 Mar; 33(3):625-637. PubMed ID: 30267008
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib treatment improves T cell number and function in CLL patients.
Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
[TBL] [Abstract][Full Text] [Related]
17. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
18. Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment.
Wu X; Thisdelle J; Hou S; Fajardo-Despaigne JE; Gibson SB; Johnston JB; Dawe DE; Banerji V; Marshall AJ
Leuk Res; 2023 Aug; 131():107315. PubMed ID: 37263073
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia.
Fernandez Botana I; Pagano G; Moussay E; Paggetti J
Oncoimmunology; 2023; 12(1):2276490. PubMed ID: 37937211
[TBL] [Abstract][Full Text] [Related]
20. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4
Roessner PM; Llaó Cid L; Lupar E; Roider T; Bordas M; Schifflers C; Arseni L; Gaupel AC; Kilpert F; Krötschel M; Arnold SJ; Sellner L; Colomer D; Stilgenbauer S; Dietrich S; Lichter P; Izcue A; Seiffert M
Leukemia; 2021 Aug; 35(8):2311-2324. PubMed ID: 33526861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
